Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Abdelfatah Saleh Hassan, H. A."'
Autor:
Abdelfatah Saleh Hassan, H. A., Mitwasi, N., Ullrich, M., Kubeil, M., Toussaint, M., Deuther-Conrad, W., Neuber, C., Arndt, C., Rodrigues Loureiro, L. R., Kegler, A., González Soto, K. E., Belter, B., Rössig, C., Pietzsch, J., Frenz, M., Bachmann, M., Feldmann, A.
Publikováno v:
Frontiers in Immunology 14(2023), 1166169
Glioblastoma (GBM) is still an incurable tumor that is associated with high recurrence rate and poor survival despite the current treatment regimes. With the urgent need for novel therapeutic strategies, immunotherapies, especially chimeric antigen r
Publikováno v:
Tumor Immunology meets Oncology (TIMO) XVII 2023 Halle, 20.-22.04.2023, Halle, Germany
Novel immunotherapeutic approaches such as chimeric antigen receptor (CAR)-expressing immune cells are showing promising results against cancer. Among these are the CAR Natural Killer (NK) cells that can be produced from either established cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4577::d6fdc8488e3c7661e97f1debd4d4bfe6
https://www.hzdr.de/publications/Publ-36995-1
https://www.hzdr.de/publications/Publ-36995-1
Autor:
Mitwasi, N., Abdelfatah Saleh Hassan, H. A., Arndt, C., Loureiro, L. R., Kegler, A., Kubeil, M., Toussaint, M., Deuther-Conrad, W., Bachmann, M., Feldmann, A.
Publikováno v:
ESMO IMMUNO-ONCOLOGY CONGRESS 2022, 07.-09.12.2022, Geneva, Switzerland
Background: Glioblastoma (GBM) is a very aggressive brain tumor, associated with poor prognosis and survival. So far, the efficiency of available therapies is limited. After proving their effectiveness in targeting hematological malignancies, chimeri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4577::32244cfb4b8f47c94752174b2aec52e0
https://www.hzdr.de/publications/Publ-35644-1
https://www.hzdr.de/publications/Publ-35644-1